CA
NZ
UK
AU
IND
US
The company's revenue also disappointed, contributing to a 4.2% decline in share price to $38.97 during after-hours trading. This underperformance comes as Harrow grapples with an 18.5% drop in shares year-to-date. Investor sentiment is particularly fragile given the company's recent acquisition plans and the …
Latigo Biotherapeutics, Inc. has secured approximately $345.6 million via its initial public offering completed on August 10, 2026. The IPO involved the sale of 19.2 million shares priced at $18.00 each, generating strong investor interest. This successfulCapitalraise marks a key moment for the company, …
Trump's latest executive order calling for a reduction in childhood vaccines has sparked considerable debate within the healthcare sector. This intervention pushes against established public health principles, linking vaccines to autism despite broad scientific consensus denouncing such claims. The administrative directive could shift attitudes …
Year-to-date, Accendra's stock is down 40.3%, reflecting deep investor discontent in the wake of the disappointing quarterly results. This decline has driven the market cap down to approximately $214 million, raising alarms over the company’s future.
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) delivered an unexpected earnings per share (EPS) of $-0.23 for the quarter ended June 30, surpassing analyst expectations that suggested a $-0.25 loss. The company's marketCapitalizationnow stands at approximately $156 million, indicating investor skepticism that could change with …
NeOnc Technologies Holdings, Inc. reported a net loss of $14.2 million for the quarter ending June 30, 2026, driven by increased research and development expenses of $2.6 million. This significant financial position reflects the company's ongoingInvestmentin itsClinical Trialsas it prepares to present key topline …
AbCelleraBiologics(NASDAQ: ABCL) disclosed that its investigational therapy ABCL‑635 lowered the frequency of moderate‑to‑severe menopausal hot flashes by 83% in a Phase II study released on 10 August 2026. The dramatic efficacy win follows a season of strong price momentum, with the stock up 172.3% …
Alumis Inc. (NASDAQ: ALMS) announced a major milestone with envudeucitinib showing a 54% PASI 100 skin clearance rate in its ongoing ONWARD3 clinical trial. This significant figure underscores the drug's efficacy as a treatment for moderate-to-severe plaque psoriasis, positioning Alumis as a competitive player …
Bionano Genomics, Inc. (NASDAQ: BNGO) announced that total revenue for Q2 2026 soared to $8.2 million, representing a 21% increase from $6.7 million year-over-year. This growth exceeded market expectations, withEarnings Per Share(EPS) registered at $-0.64, better than the anticipated $-0.70. Such performance highlights an …
BridgeBio Pharma, Inc. (NASDAQ: BBIO) reported second-quarter revenues of $243.7 million, primarily driven by $222.4 million from the U.S. net product sales of its treatment, Attruby. This total reflects a growing acceptance of Attruby in the market, particularly among treatment-naïve patients. However, the company …
Please wait processing your request...